Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Flora M Haaijer-Ruskamp

Showing results (31-40 of 96) with videos related to

Pageof 10
Sort By:
Drug Safety|November 15, 2011
Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011Liana Hakobyan, Flora M Haaijer-Ruskamp, Dick de Zeeuw, et al.
Journal of Cardiac Failure|February 10, 2010
The impact of perceived adverse effects on medication changes in heart failure patientsRuth H E De Smedt, Tiny Jaarsma, Flora M Haaijer-Ruskamp, et al.
Drugs & Aging|November 21, 2007
beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerabilityDaniela Dobre, Flora M Haaijer-Ruskamp, Adriaan A Voors, et al.
BMJ Quality & Safety|February 7, 2013
Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT databaseGrigory Sidorenkov, Jaco Voorham, Dick de Zeeuw, et al.
Health and Quality of Life Outcomes|August 14, 2014
Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional studySieta T de Vries, Flora M Haaijer-Ruskamp, Dick de Zeeuw, et al.
Diabetes Care|December 12, 2007
Influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetesJaco Voorham, Flora M Haaijer-Ruskamp, Ronald P Stolk, et al.
Clinical Therapeutics|March 15, 2011
Medication adherence affects treatment modifications in patients with type 2 diabetesJaco Voorham, Flora M Haaijer-Ruskamp, Bruce H R Wolffenbuttel, et al.
Pharmacoepidemiology and Drug Safety|June 19, 2003
Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000Lisa G Pont, Miriam C Sturkenboom, Wiek H van Gilst, et al.
Cardiovascular Diabetology|September 22, 2007
Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational studyJacoba P Greving, Petra Denig, Dick de Zeeuw, et al.
European Journal of Clinical Pharmacology|March 12, 2005
Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel studyWilleke N Kasje, Petra Denig, Roy E Stewart, et al.
Pageof 10

Showing results (31-40 of 96) with videos related to

Sort By:
Pageof 10
Drug Safety|November 15, 2011
Comparing adverse event rates of oral blood glucose-lowering drugs reported by patients and healthcare providers: a post-hoc analysis of observational studies published between 1999 and 2011Liana Hakobyan, Flora M Haaijer-Ruskamp, Dick de Zeeuw, et al.
Journal of Cardiac Failure|February 10, 2010
The impact of perceived adverse effects on medication changes in heart failure patientsRuth H E De Smedt, Tiny Jaarsma, Flora M Haaijer-Ruskamp, et al.
Drugs & Aging|November 21, 2007
beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerabilityDaniela Dobre, Flora M Haaijer-Ruskamp, Adriaan A Voors, et al.
BMJ Quality & Safety|February 7, 2013
Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT databaseGrigory Sidorenkov, Jaco Voorham, Dick de Zeeuw, et al.
Health and Quality of Life Outcomes|August 14, 2014
Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional studySieta T de Vries, Flora M Haaijer-Ruskamp, Dick de Zeeuw, et al.
Diabetes Care|December 12, 2007
Influence of elevated cardiometabolic risk factor levels on treatment changes in type 2 diabetesJaco Voorham, Flora M Haaijer-Ruskamp, Ronald P Stolk, et al.
Clinical Therapeutics|March 15, 2011
Medication adherence affects treatment modifications in patients with type 2 diabetesJaco Voorham, Flora M Haaijer-Ruskamp, Bruce H R Wolffenbuttel, et al.
Pharmacoepidemiology and Drug Safety|June 19, 2003
Trends in prescribing for heart failure in Dutch primary care from 1996 to 2000Lisa G Pont, Miriam C Sturkenboom, Wiek H van Gilst, et al.
Cardiovascular Diabetology|September 22, 2007
Trends in hyperlipidemia and hypertension management in type 2 diabetes patients from 1998-2004: a longitudinal observational studyJacoba P Greving, Petra Denig, Dick de Zeeuw, et al.
European Journal of Clinical Pharmacology|March 12, 2005
Physician, organisational and patient characteristics explaining the use of angiotensin converting enzyme inhibitors in heart failure treatment: a multilevel studyWilleke N Kasje, Petra Denig, Roy E Stewart, et al.
Pageof 10